EMEA-000019-PIP01-07 - paediatric investigation plan

everolimus

Key facts

• Active Substance:
  everolimus
• Therapeutic area:
  Oncology
• Decision number:
  P/2/2007
• PIP number:
  EMEA-000019-PIP01-07
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Renal cell carcinoma and pancreatic neuroendocrine tumour
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/12/2007

Decision

P/2/2007: European medicines agency decision of 11 December 2007 on the application for a product specific waiver for Everolimus (EMEA-000019-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parl...

AdoptedReference Number: EMEA/575610/2007